Dr. Yi-Chung Chao, director and the chief medical officer of Regencell Bioscience Holdings Limited, a company
incorporated under the laws of the Cayman Islands (the "Company"), has resigned from his position as chief
medical officer for personal reasons, with effect from December 28, 2022. Dr. Chao's resignation was not a
result of any disagreements with the Company or any of its subsidiaries and affiliates on any matter related to
the operations, policies, or practices of the Company or any of its subsidiaries and affiliates. Dr. Chao will
continue to serve as a director of the Company. Dr. Chao will remain with the Company in an advisory role for
a period of 12 months to assist with an orderly transition. The responsibilities of the chief medical officer are being assumed by Ms. Antonia Assang in her current role
as senior vice president (project management) of the Company until a new chief medical officer is appointed.